Navigation Links
IRS Awards $244,479 Grant to STB Lifesaving Technologies®
Date:11/3/2010

ROCKVILLE, Md., Nov. 3, 2010 /PRNewswire/ -- STB Lifesaving Technologies® today announced that it has been awarded a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. government in the amount of $244,479.  

The Qualifying Therapeutic Discovery Project was included in the Health Care Reform Bill to foster medical, life science, and biological innovation in the U.S., and the grant was based upon research expenditures for its lead product, the Fibrin Adhesive STat®, or FAST® dressing.

STB® has conducted successful animal studies for the FAST® dressing with both military and commercial partners and is further supported by published data from the American Red Cross.  

In these published comparative animal studies, Fibrin Adhesive STat®, or FAST® dressing has proven to be functionally superior to commercially available products in significantly reducing blood loss.  The FAST® dressing contains large quantities of the human blood clotting proteins fibrinogen, thrombin, and Factor XIII in a dry form. Once in contact with the wound, the components in the FAST® dressing are instantly activated to form a fibrin clot similar to that which results from the body's own clotting process.

Last month STB® announced that it had completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA).

"This additional funding will accelerate the remaining pre-IND development work and animal studies for the FAST® dressing already underway," said Richard Moscarello, CEO of STB®. "We appreciate the government's continued support for this product which soon will be translated into saving military and civilian lives."

About STB®  

Founded in 2005, STB Lifesaving Technologies® (STB®) is a privately held, pre-clinical stage, biotechnology development company located in Rockville, Maryland. STB® which stands for "stop the bleeding", is focused on developing a comprehensive suite of products to stop serious and life threatening bleeding in trauma and surgical settings. With a strong proprietary position using its all-natural protein technology with five patents and one provisional patent pending, STB®'s products will be indispensable to both the military and civilian medical markets.

www.stblifesaving.com


'/>"/>
SOURCE STB Lifesaving Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
3. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
4. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
5. Small Business Innovation Research Program Awards Grant to Biomoda
6. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
7. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
8. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
9. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
10. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
11. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... Treated at Proton Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in ... from its market value in 2016. There are currently three proton therapy ... capacity to treat more patients. In Italy , the ...
(Date:3/29/2017)... 29, 2017  Providence Medical Technology, Inc., an ... of two industry veterans to the commercial leadership ... company to lead Global Marketing, and Michael ... Lynch and Mr. Scott have over 40 years ... Lynch joins the company with over 22 years ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 million SharePoint ... option for on-premises installation of its Help System for SharePoint was at the farm ... into the entire tenant. , The company recently released a modified version of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the annual ... the Diabetes Risk Test to find out if they are at risk for developing ... light up the evening sky by programming the LAX pylons the color red. Downtown’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s Chigurupati Technologies ... directly address the resolution to globally reduce the harmful use of alcohol set ... FDA and TTB approved ingredients that when infused into alcohol, renders the alcohol ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to be invited to the Siemens Healthineers annual customer education symposium, a world-class ... will take place from March 27 - 31, 2017 at the Atlanta Marriott ...
(Date:3/28/2017)... ... March 29, 2017 , ... ... pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March ... common questions regarding thyroid function. , Dr. Izabella Wentz is a licensed ...
Breaking Medicine News(10 mins):